SJP-007

SJP-007 is a small molecule drug candidate being developed by Sen-Jam Pharmaceutical for the treatment of opioid tolerance. It is part of a broader anti-inflammatory platform that utilizes repurposed small molecules. The drug's mechanism of action involves the dual inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, alongside the stabilization or modulation of mast cells. By targeting these inflammatory pathways, SJP-007 aims to reduce the development of tolerance to various opioids, including oxycodone, morphine, and heroin, potentially allowing for more effective pain management with lower doses and reduced risk of dose escalation.